FORECAST OF THE GLOBAL COAGULATION
FACTORS CONCENTRATES MARKET 2010 to 2025
This report forecasts the global consumption of clotting factors (factors VIII, IX and von Willebrand factor, as well as bypassing agents) to 2025 in units and dollars in over 150 countries, under likely, pessimistic, and optimistic scenarios.
The goal of this study is to provide strategic insight to business development and production plans in the context of growing global demand and the emergence of new technologies such as longer half-life coagulation factor products and gene therapy.
Specific country information and assumptions were used to develop yearly forecasts of coagulation factor demand in each country from 2010 to 2025. The data distinguish the use of a) cryoprecipitate, b) plasma-derived coagulation factors and c) recombinant factor concentrates, including such novels agents as fusion-protein and long-acting factors. Dollar sales by product category have been estimated, using pricing assumptions over the forecast period.
The study does not take production constraints into consideration, but rather guide the clients towards the development of optimal production levels.
Statistical models have been developed to build sales forecasts of factor VIII, factor IX, von Willebrand factor and factor bypassing agents. Secondary data such as population, disease prevalence, patient registry, and other published sources, including proprietary MRB data were used to develop the initial baseline market profile and the forecasts.
The forecasts of factor VIII, factor IX, von Willebrand factor and inhibitor market may be purchased separately. The table of contents of the report and an order form are enclosed.
Forecast of the Global Coagulation Factors Concentrates Market
2010 to 2025
TABLE OF CONTENTS
Factor VIII – Hemophilia A
Factor IX – Hemophilia B
vW Factor – von Willebrand Deficiency
Inhibitor Bypass Agents
Description of the Model Function
Directions for Model’s Assumptions Changes